INmune Bio
INMB • NASDAQ
INmune Bio is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO David J. Moss, with a market cap of $29.8M.
CEODavid J. Moss
Next Earnings
Upcoming earnings announcement for INmune Bio
Date
Thursday, May 7, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.33
Earnings History
Past 11 earnings reports for INmune Bio
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Oct 30, 2025 | Q3 2025 | -$0.24Est: -$0.32 | +25.0% | - | — |  10-Q |
| Aug 7, 2025 | Q2 2025 | -$0.34Est: -$0.38 | +10.5% | - | — | 10-Q |
| May 8, 2025 | Q1 2025 | -$0.43Est: -$0.46 | +6.5% | $50.0K | — | 10-Q |
| Mar 27, 2025 | Q4 2024 | -$0.40Est: -$0.53 | +24.5% | - | — | 10-K |
| Oct 31, 2024 | Q3 2024 | -$0.60Est: -$0.50 | -20.0% | - | — | 10-Q |
| Aug 1, 2024 | Q2 2024 | -$0.50Est: -$0.63 | +20.6% | - | — | 10-Q |
| May 9, 2024 | Q1 2024 | -$0.61Est: -$0.53 | -15.1% | $14.0KEst: $30.0K | -53.3% | 10-Q |
| Mar 28, 2024 | Q4 2023 | -$0.47Est: -$0.44 | -6.8% | $28.0KEst: $40.0K | -30.0% | 10-K/A |
| Nov 1, 2023 | Q3 2023 | -$0.48Est: -$0.41 | -17.1% | $43.0K | — | — |
| Aug 7, 2023 | Q2 2023 | -$0.36Est: -$0.40 | +10.0% | $46.0K | — | 10-Q |
| May 3, 2023 | Q1 2023 | -$0.36Est: -$0.02 | -1700.0% | $38.0K | — | — |